Bladder cancer markers in patient management: The current perspective

World Journal of Urology

Volumn 26, Issue 1, 2008, Pages 1-3

  Schmitz Drager B J ^a   Fradet, Y ^b   Grossman, H B ^c  

^a EuromedClinic ^*  (Germany)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BLADDER TUMOR; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HUMAN; SENSITIVITY AND SPECIFICITY; URINE;

DIAGNOSIS, DIFFERENTIAL; HUMANS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 39349104911     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0225-0     Document Type: Editorial

References (13)

1. Oosterlinck W, v d Meijden A, Sylvester R et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. In: Aus G, Hanus T, Irani J et al. (eds) European Association of Urology: Guidelines 2007 edition, 3-17
2. Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ (2005) Concepts for banking tissue in urologic oncology - the international bladder cancer bank. Clin Cancer Res 11:413-15
3. Goebell P, Groshen S, Schmitz-Drüger BJ (2007) Guidelines for development of diagnostic markers in bladder cancer. World J Urol
4. Madep R, Messing EM (2007) Long-term outcome of home dip-stick testing for hematuria. World J Urol
5. Lotan Y, Shariat S, Malats N (2007) Screening for bladder cancer - a perspective? World J Urol
6. Chiong E, Gaston KE, Grossman HB (2007) Urinary Markers in bladder cancer screening. World J Urol
7. Schmitz-Dräger BJ, Tirsar L-A, Schmitz-Dräger C, Mellan Z, Dörsam J, Bismarck E, Ebert T (2007) Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urolc
8. Kamat AM, Agarwal P (2007) Practical considerations in the use of diagnostic bladder cancer markers in patient management. World J Urol
9. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S (2002) Delay and survival in bladder cancer. BJU Int 89(9):868-878
10. Liedberg F, Anderson H, Mansson A, Mansson W (2003) Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol 37:396-400
11. Raitanen M and the FinnBladder group (2007) The role of BTA stat test in follow up of patients with bladder cancer - results from FinnBladder trials. World J Urol
12. Nguyen CT, Jones J (2007) Defining the role of NMP22 in bladder cancer surveillance. World J Urol
13. Beiche B, Ebert T, Schmitz-Drüger BJ (2002) Immunzytologie in der Diagnostik des Urothelkarzinoms'ein reproduzierbares Testverfahren? Urologe A 41(Suppl 1):45